GlassScriptPhysician profile
I-Tsyr Shaw
NPI 1104026558
$3,136.91
in general payments reported to CMS, 2019-2025
27 companies · $415 in 2025
The $415 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $734 · 2021: $260 · 2022: $461 · 2023: $606 · 2024: $541 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,561.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,561.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $587.61 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $443.87 | 2019-2025 | Mounjaro, Zepbound, Baqsimi |
| Tandem Diabetes Care, INC. | $337.10 | 2020-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $326.65 | 2020-2025 | Freestyle Libre 3 |
| Insulet Corporation | $187.10 | 2019-2023 | Omnipod |
| Amgen INC. | $165.72 | 2019-2025 | Tepezza, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $164.37 | 2020-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.75 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $85.95 | 2020-2024 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $73.84 | 2023-2025 | |
| Sanofi Pasteur INC. | $72.01 | 2022-2024 | |
| Antares Pharma, INC. | $65.62 | 2024 | Xyosted |
| Amarin Pharma, INC. | $64.43 | 2020 | |
| Ascendis Pharma Endocrinology INC | $56.88 | 2024-2025 | Yorvipath |
| Dexcom, INC. | $55.83 | 2022-2023 | Dexcom G6 Transmitter |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $47.22 | 2022 | |
| Mannkind Corporation | $43.94 | 2023-2025 | Afrezza |
| Radius Health, INC. | $43.40 | 2019 | |
| Halozyme INC | $35.89 | 2023 | |
| Medtronic, INC. | $34.65 | 2024 | Minimed 780g |
| Phadia US INC. | $31.64 | 2023-2025 | Immunocap |
| Exact Sciences Corporation | $31.28 | 2025 | The Cologuard Plus Collection Kit |
| Alkermes, INC. | $20.36 | 2023 | Vivitrol |
| Medtronic Minimed, INC. | $16.23 | 2020 | |
| Lnhc, INC | $14.85 | 2025 | Zelsuvmi |
| Becton, Dickinson and Company | $14.70 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw I-Tsyr Shaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.